Inceptua Group, Author at Inceptua Group

Inceptua Group Announces Partnership with BioCryst on Expanded Access Program for Patients with Hereditary Angioedema

LUXEMBOURG – June 26, 2020 –Inceptua Group – pharmaceutical company and service partner spanning throughout the product lifecycle – from clinical trial comparator sourcing, packaging, labelling, and distribution solutions, through…

Inceptua GroupJune 26, 2020

Clinical Trial Services Featured

Safely and Reliably Supplying your Comparator Needs during COVID19

Maintaining Safe and Reliable Supply of Comparators during COVID19 As an agile, well-distributed and robust global supplier of Comparators for the biopharmaceutical industry, Inceptua is uniquely positioned to safely and…

Inceptua GroupJune 4, 2020

Medicines Access

Maintaining access to your medicines during COVID19

As an agile, global, and robust provider of medicines access programs for the biopharmaceutical industry, Inceptua is uniquely positioned to safely and reliably supply your products throughout the global crisis.…

Inceptua GroupJune 4, 2020

Featured Press release

Global License Agreement a Building Block in Strategic Growth Plans

LUXEMBOURG – 23 March, 2020 – Inceptua – pharmaceutical company and service partner - and biopharmaceutical company Oxurion have announced a global license agreement for the commercialization of JETREA®, a…

Inceptua GroupMarch 23, 2020

Clinical Trial Services Featured

How we are supporting with uninterrupted supply of medicines for clinical trials

In clinical trials, a Comparator drug, either an investigational or marketed product, is often required to determine the efficacy relative to a drug that is already on the market. Safe,…

Inceptua GroupMarch 22, 2020

Featured Press release

Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA®

Press release: Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA® Oxurion announces the signing of a JETREA® global license agreement with Inceptua Group. JETREA® is…

Inceptua GroupMarch 13, 2020

Featured Press release

Inceptua and Portola enter exclusive distribution agreement for Ondexxya®

LUXEMBOURG / SAN FRANCISCO – 7th February 2020 – Inceptua, a global pharmaceutical company and service partner and Portola - US developer and manufacturer of therapeutic agents focusing on thrombosis…

Inceptua GroupFebruary 7, 2020

Featured Press release

Inceptua appoints new Head of Asia-Pacific, Clinical Trial Services

Inceptua has offices in both Japan and China where the regional Clinical Trial Services Team provides strategic sourcing and supply of clinical trial materials with associated clinical packaging and labelling…

Inceptua GroupFebruary 5, 2020

Uncategorized

Season’s Greetings

Dear Partner, It’s December, and the Holiday season is upon us. As we approach the turn of the year, we want to send our warmest wishes and our thanks for a wonderful…

Inceptua GroupDecember 18, 2019

Press release

Inceptua and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US

NEWTOWN, PA., and LUXEMBOURG, Dec 6, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with…

Inceptua GroupDecember 6, 2019